Study S001557

A 52-Week, Open-Label, Multicenter Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01777282
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 374
Start: 2013-02-23
Primary completion: 2015-01-27
Lead sponsor: GlaxoSmithKline
Conditions: Diabetes Mellitus
Interventions: DRUG:Albiglutide; DRUG:Sulfonylurea; DRUG:Biguanide; DRUG:Glinide; DRUG:Thiazolidinedione; DRUG:Alpha-glucosidase inhibitor
Results posted: TRUE
Individual participant data sharing: YES

Registered primary outcomes

Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) [From Baseline through Week 52]
Number of Participants With Any Hypoglycemic Event [From Baseline through Week 52]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0021319	Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs. Okuda I, Current medical research and opinion	2017	Randomized trial	PMID 27852119 DOI	cites ClinicalTrials.gov:NCT01777282; registry reference DERIVED:27852119